Redefining Available Therapy in Oncology Accelerated Approval Decisions
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco.24.00892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Shruti Rajesh Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA. Hauptthemen laut MEDLINE: Drug Approval, Neoplasms, Medical Oncology, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
When weighing rapid approval for follow-on drugs, should @FDAOncology recognize the drugs that came before?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
- Department of Internal Medicine, UCLA-Olive View, Sylmar, CA.
ORCID-Profile: Shruti Rajesh Patel, Christopher T Chen
Zitieren
APA
Patel, S. R., Ramachandran, M., Ai, A., & Chen, C. T. (2025). Redefining Available Therapy in Oncology Accelerated Approval Decisions. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00892
Vancouver
Patel SR, Ramachandran M, Ai A, Chen CT. Redefining Available Therapy in Oncology Accelerated Approval Decisions. Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00892
BibTeX
@article{Patel2025,
author = {Patel, Shruti Rajesh and Ramachandran, Maya and Ai, Angela and Chen, Christopher T},
title = {Redefining Available Therapy in Oncology Accelerated Approval Decisions},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.24.00892}
}
EUVIMED